Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.36 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30872619 | 1.00 | JAK3 (0.42) | JAK3LRRK2CDK1JAK2JAK1 | |
| SCHEMBL6266762 | 0.81 | CDK2 (0.48) | CDK1CCNB2CCNB1CCNA2CDK2 | |
| SCHEMBL8830357 | 0.78 | CDK2 (0.40) | JAK3LRRK2CDK1JAK2JAK1 | |
| SCHEMBL9204246 | 0.78 | JAK3 (0.58) | JAK3LRRK2CDK1JAK2JAK1 | |
| SCHEMBL9204849 | 0.76 | JAK3 (0.56) | JAK3LRRK2CDK1JAK2JAK1 | |
| SCHEMBL31380770 | 0.73 | XDH (0.37) | — | |
| SCHEMBL1443986 | 0.73 | XDH (0.37) | — | |
| SCHEMBL5439050 | 0.72 | KMT2A (0.51) | PAK1 | |
| SCHEMBL183228 | 0.72 | KMT2A (0.51) | PAK1 | |
| SCHEMBL5442344 | 0.72 | KMT2A (0.51) | PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | TYMP, HPRT1, IMPDH1 | JAK3 2341/4885LRRK2 4185/4885CDK1 213/4885 |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | JAK3 583/4885LRRK2 3245/4885CDK1 3187/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | JAK3 1555/4885LRRK2 1389/4885CDK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.